Ge Long Hui A P P·2026-02-24 08:42Core Viewpoint - The company received approval from the National Medical Products Administration for an expanded age range for its ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier), now applicable for children aged 3 months to 6 years [1] Group 1 - The product, known as Manhaixin®, is the first quadrivalent meningococcal conjugate vaccine approved in China, which was launched in December 2021 [1] - The approval helps to narrow the gap between China and developed countries in the field of high-end vaccines, addressing the lack of such vaccines in the country [1] - Manhaixin® provides a superior solution for the prevention of meningococcal disease in children aged 6 years and below, demonstrating strong market performance and increasing market share [1]